Mirvaso

Mirvaso gel contains brimonidine tartrate 3 mg/g and is a prescription treatment for the facial redness (erythema) associated with rosacea in adults. Brimonidine is a selective alpha-2 adrenergic receptor agonist that causes vasoconstriction of the superficial blood vessels in the skin, temporarily reducing the redness characteristic of rosacea.

Understanding Rosacea Erythema

Rosacea is a chronic inflammatory skin condition that primarily affects the face, causing persistent redness, visible blood vessels, and sometimes papules and pustules. The facial flushing and erythema in rosacea result from abnormal vascular reactivity and dilation of superficial facial blood vessels. Mirvaso addresses this specific symptom by constricting these vessels, providing a visible reduction in redness for up to 12 hours after a single application.

Effectiveness

In clinical trials, Mirvaso gel produced a clinically meaningful reduction in facial erythema in the majority of patients within 30 minutes of application, with effects persisting for up to 12 hours. It is applied once daily and is designed to be used as needed rather than continuously.

How to Apply Mirvaso

Apply a pea-sized amount of Mirvaso (brimonidine gel) to each of the five facial areas (forehead, chin, nose, and each cheek) once daily. Spread evenly across the affected areas, avoiding the eyes, eyelids, and lips. Wash your hands before and after application. Allow the gel to dry before applying other skincare products or cosmetics.

Start with a smaller amount than you think you need, as using too much increases the risk of side effects. Do not apply more than the recommended amount, and never apply more than once per day. The redness-reducing effect begins within 30 minutes and lasts approximately 8 to 12 hours.

Mirvaso is available as a 30 g tube of 0.33% (3 mg/g) gel. Apply a pea-sized amount to each of five facial areas once daily. Do not exceed the recommended dose. Store at room temperature below 25°C. Keep away from children.

Common Side Effects

The most frequently reported local side effects include erythema worsening (paradoxical erythema), flushing, skin burning sensation, contact dermatitis, and pruritus (itching). These tend to occur after several weeks of use. Some patients experience a rebound increase in redness as the medication wears off.

Systemic Effects

Although brimonidine is applied topically, some systemic absorption can occur. Systemic side effects are uncommon but include dizziness, headache, hypotension (low blood pressure), and bradycardia (slow heart rate). Pallor (excessive skin blanching) has been reported and may be distressing to some patients. If you experience pronounced pallor, reduce the amount applied or stop use and contact your prescriber.

Mirvaso gel must not be applied to the eyes or mucous membranes. Avoid getting the gel on broken or irritated skin. Use with caution in patients with cardiovascular disease, orthostatic hypotension, depression, cerebrovascular disease, Raynaud's phenomenon, or Sjogren's syndrome. Avoid concurrent use of monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants. Not recommended in children under 18 years.

Contraindicated in patients with hypersensitivity to brimonidine or any excipient. Not recommended for use in neonates and infants due to potential for CNS depression. Exercise caution in patients with cardiovascular, hepatic, or renal impairment.